

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE PATENT TRIAL AND APPEAL BOARD**

FRESENIUS KABI USA LLC

Petitioner,

v.

CUBIST PHARMACEUTICALS, INC.

Patent Owner.

Case: IPR2015-01571
Patent No. 8,058,238

JOINT MOTION TO LIMIT PETITION UNDER 37 C.F.R. § 42.71

I. STATEMENT OF THE PRECISE RELIEF REQUESTED

Pursuant to 37 C.F.R. § 42.25 and an email authorizing this motion in *Inter Partes* Review IPR2015-01571, which concerns U.S. Patent No. 8,058,238 (“the ’238 Patent”)¹ Petitioner Fresenius Kabi USA LLC (“Fresenius”) and Patent Owner Cubist Pharmaceuticals LLC (“Cubist”) jointly request that the Board (1) limit the petition to claims 98 and 187, and (2) remove 1-19, 21-44, 48-51, 53, 92-97, 99-107, 112-146, 151-167, 176, 177, 179, 183-186 and 188-189 of the ’238 Patent from this consideration in this proceeding.

II. STATEMENT OF FACTS

Fresenius filed a petition for *inter partes* review on July 10, 2015, requesting review of claims 1-19, 21-44, 48-51, 53, 92-107, 112-146, 151-167, 176, 177, 179, and 183-189 of the ’238 Patent. This proceeding is still in its preliminary stages, and the Board has not yet decided whether to institute trial.

Fresenius and Cubist are parties to a litigation concerning the ’238 patent in the United States District Court for the District of Delaware, *Cubist Pharmaceuticals, Inc., v. Fresenius Kabi USA, LLC*, C.A. No. 14-914-GMS

¹ August 25, 2015 email from Maria Vignone, Paralegal Operations manager, Patent Trial and Appeal Board to Cynthia Lambert Hardman and other.

(D.Del.).² In the Delaware Litigation, on August 10, 2015, Fresenius and Cubist filed, under seal, a Stipulation and Agreement to Narrow Issues in the Litigation and IPR Proceedings and Covenant Not to Sue (“Stipulation and Agreement”), wherein the parties agreed to narrow the issues in dispute in both the litigation and in this *inter partes* review by, *inter alia*, seeking to remove claims 1-19, 21-44, 48-51, 53, 92-97, 99-107, 112-146, 151-167, 176, 177, 179, 183-186 and 188-189 of the ’238 patent from consideration in this proceeding.³

III. ARGUMENT

A. Limiting the Petition in IPR2015-01571 is Appropriate

The parties respectfully submit that the Board should limit the petition in IPR2015-01571 for at least the following reasons.

² The district court litigation also involves U.S. Patent Nos. 6,468,967, 6,852,689, and 8,129,342, and Fresenius has filed petitions for *inter partes* review concerning each of these patents, and additional petitions on the ’238 patent. *See* IPR2015-00223, IPR2015-00227, IPR2015-01566, IPR2015-01570, and IPR2015-01572.

³ A redacted public version of the Stipulation and Agreement was filed on August 17, 2015.

First, the parties are filing this joint motion before the Board has decided the merits of the proceeding. Indeed, the Patent Owner's Preliminary Response is not yet due, and the Board has not yet decided whether to institute trial.

Second, the parties have agreed to limit this proceeding in connection with a broader agreement to narrow the disputed issues in several co-pending proceedings, including multiple *inter partes* reviews and a district court litigation.

Third, because the merits of the petition have not been determined, reducing the number of claims at this early juncture promotes efficient use of the resources of the Board, and saves expenses for the parties.

B. A Copy of the Stipulation is Provided

The Stipulation and Agreement has been made in writing, and a true copy is filed herewith as business confidential information pursuant to 35 U.S.C. § 317(b) and 37 C.F.R. § 42.74, as Exhibit 1041. A Joint Request to File an Agreement as Business Confidential Information under 35 U.S.C. § 317(b) and 37 C.F.R. § 42.74 is also being filed herewith. The redacted public version of the Stipulation and Agreement filed in the district court litigation is also submitted herewith as Exhibit 1042.

C. Summary

For the foregoing reasons, Fresenius and Cubist respectfully request that the Board limit the petition to claims 98 and 187, and remove claims 1-19, 21-44, 48-

51, 53, 92-97, 99-107, 112-146, 151-167, 176, 177, 179, 183-186 and 188-189
from consideration in this proceeding.

Dated: September 1, 2015

Respectfully submitted,

/Elizabeth J. Holland/

Elizabeth J. Holland

Reg. No. 47,657

Lead Attorney for Petitioner Fresenius Kabi
USA LLC

Dated: September 1, 2015

Respectfully submitted,

/Emily R. Whelan/

Emily R. Whelan

Reg. No. 50,391

Lead Attorney for Patent Owner Cubist
Pharmaceuticals LLC

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.